2026-10-19T01:56:33Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/144602026-10-18T21:14:22Zopenairedrivercom_ebyu_10000col_ebyu_10001

A novel therapeutics agent: antioxidant effects of hydroxylfasudil on rat kidney and liver tissues in a protamine sulphate-induced cystitis rat model; preliminary resultsBozkurt, AliseydiBudak, HarunErol, Huseyin SerkanCan, SerpilMercantepe, TolgaAkin, YigitOzbey, IsaCankaya, MuratHalici, Mesut BunyaminCoban, T. Abdulkadirenzyme activityexpressionhydroxyfasudilInterstitial cystitiskidneyliver1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsAntioxidantsCatalaseCystitisDisease Models, AnimalGlutathioneLipid PeroxidationProtaminesRatsSuperoxide DismutaseHistologyPathologySulfur compoundsTissueprotamine sulfate1 (5 isoquinolinesulfonyl) 2 methylpiperazineantioxidantprotamineBacterial infectionsLipid peroxidation levelsQuantitative changesSuperoxide dismutasesanimal experimentCystitis is defined as an inflammation of the bladder caused by a bacterial infection, and it can be dangerous and painful when it spreads through the internal organs. In this study, antioxidant effects of hydroxylfasudil (HF) at the enzymatic and molecular level on kidney and liver tissues in cystitis rat model, which is caused by inflammation of the rat bladder with a protamine sulphate (PS), was examined. Quantitative changes of reduced glutathione (GSH) and lipid peroxidation (LPO) levels, which are a marker for oxidative stress, were determined in rat kidney and liver tissues for each groups. And then molecular and biochemical impact of HF treatment on antioxidant enzymes including superoxide dismutase (SOD) and catalase (CAT) in cystitis model were studied. The results suggest that HF could be beneficial to the renal and hepatic antioxidant system. Thus, HF might be used as a novel therapeutics agent to eliminate interstitial cystitis. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.Taylor and Francis Ltd.2018Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/14460https://doi.org/10.1080/21691401.2018.14491202169-1401enArtificial Cells, Nanomedicine and Biotechnologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14460